Drugs / phenethyl isothiocyanate
phenethyl isothiocyanate
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00968461 | May 2013 → May 2015 | leukemia, lymphoproliferative syndrome | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT00005883 | ? → Apr 2001 | lung cancer | NYU Langone Health | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT00691132 | Feb 2009 → Jan 2013 | lung cancer, nicotine dependence | University of Minnesota | Completed | Met primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | phenethyl isothiocyanate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005883 ↗ |
| Known as | 2-Phenethyl isothiocyanate | “2-Phenethyl isothiocyanate (PEITC), a natural product found as a conjugate in watercress and other cruciferous vegetables, is an inhibitor of the metabolic activation and lung...” PMID 26951845 ↗ Mar 2016 |
| Known as | PEITC | “Phenethyl Isothiocyanate (PEITC)” NCT00968461 ↗ |
| Action | Inhibit | “is an inhibitor of the metabolic activation and lung carcinogenicity of the tobacco carcinogen” PMID 26951845 ↗ Mar 2016 |
| Modality | Small molecule | — CHEMBL151649 ↗ |
| Route | Oral | “Patients receive phenethyl isothiocyanate orally 4 times a day for 30 days.” NCT00005883 ↗ |